{"subsection_name": "Money &amp; Policy", "pub_date": "2011-10-04T09:51:25Z", "byline": {"original": "By ANDREW POLLACK", "person": [{"lastname": "POLLACK", "organization": "", "rank": 1, "role": "reported", "firstname": "Andrew"}]}, "abstract": "A spate of infections, leaving some patients blind, has caused some physicians to choose the more expensive Lucentis for eye disease in the elderly.", "word_count": "995", "print_page": null, "news_desk": null, "snippet": "A spate of infections, leaving some patients blind, has caused some physicians to choose the more expensive Lucentis for eye disease in the elderly.", "multimedia": [], "source": "The New York Times", "blog": [], "keywords": [], "type_of_material": "Blog", "lead_paragraph": null, "web_url": "http://prescriptions.blogs.nytimes.com/2011/10/04/doctors-grow-wary-of-avastin-for-eye-treatment/", "section_name": "Health", "headline": {"main": "Doctors Grow Wary of Avastin for Eye Treatment", "print_headline": "Risk Reports Chill the Use of a Cheaper Eye Drug", "kicker": "Prescriptions Blog"}, "slideshow_credits": null, "_id": "54f3d8f538f0d84018917f5a", "document_type": "blogpost"}